# Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)

> **NCT02051673** · — · NO_LONGER_AVAILABLE · sponsor: **Talaris Therapeutics Inc.**

## Conditions studied

- Renal Failure

## Interventions

- **BIOLOGICAL:** Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion

## Key facts

- **NCT ID:** NCT02051673
- **Lead sponsor:** Talaris Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02051673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02051673, "Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02051673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*